Drug Profile
Omipalisib - GlaxoSmithKline
Alternative Names: 2126458; GSK-212; GSK-2126458; GSK-458Latest Information Update: 09 Aug 2022
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; GSK
- Class Antineoplastics; Benzene derivatives; Fluorobenzenes; Pyridazines; Pyridines; Quinolines; Small molecules; Sulfonamides
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia
- No development reported Idiopathic pulmonary fibrosis; Lymphoma; Solid tumours
Most Recent Events
- 09 Jun 2022 Pharmacodynamics data from a cell line study in acute myeloid lukaemia presented at the 27th Congress of the European Haematology Association (EHA-2022)
- 11 Dec 2021 Preclinical trials in Acute myeloid leukaemia in United Kingdom (PO)
- 11 Dec 2021 Pharmacodynamics data from a preclinical study in Acute myeloid leukemia presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2021)